1	
2	
3	
4	Outcomes of percutaneous transhepatic gallbladder
5	drainage versus percutaneous transhepatic biliary
6	drainage for obstructive jaundice
7	
8	Short title: Usefulness of PTGBD and PTBD in patients with obstructive jaundice.
9	
10	
11	Tetsushi Azami <sup>1*</sup> , Yuichi Takano <sup>1</sup> , Naoki Tamai <sup>1</sup> , Jun Noda <sup>1</sup> , Masataka Yamawaki <sup>1</sup> ,
12	Fumitaka Niiya <sup>1</sup> , Naotaka Maruoka <sup>1</sup> , Fumiya Nishimoto <sup>1</sup> , Akira Ishihara <sup>2</sup> , Masatsugu
13	Nagahama <sup>1</sup>
14	
15	
16	
17	<sup>1</sup> Department of Medicine, Division of Gastroenterology, Showa University Fujigaoka
18	Hospital, Yokohama, Japan
19	<sup>2</sup> Department of Gastroenterological Surgery, Hitachi Medical Center, Hitachi, Japan NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 20

- 21 \* Corresponding author
- 22 E-mail: tetsushiazami@yahoo.co.jp (TA)
- 23

#### **Author contributions** 24

- 25 Conceptualization: Tetsushi Azami.
- Data curation: Tetsushi Azami. 26
- 27 Formal analysis: Tetsushi Azami.
- 28 Investigation: Tetsushi Azami, Naoki Tamai, Jun Noda, Masataka Yamawaki.
- 29 Methodology: Tetsushi Azami, Yuichi Takano, Fumitaka Niiya.
- 30 Project administration: Tetsushi Azami.
- 31 Supervision: Akira Ishihara, Masatsugu Nagahama.
- 32 Writing - original draft: Tetsushi Azami, Yuichi Takano.
- 33 Writing - review & editing: Tetsushi Azami, Yuichi Takano, Fumitaka Niiya, Naotaka
- 34 Maruoka, Fumiya Nishimoto, Akira Ishihara, Masatsugu Nagahama.

35

## 37 Abstract

38	Percutaneous transhepatic gallbladder drainage (PTGBD) is an alternative to
39	percutaneous transhepatic biliary drainage (PTBD) for cases of obstructive jaundice in which
40	the bile duct obstruction is below the confluence of the cystic ducts. The present study aimed
41	to evaluate the usefulness of PTGBD and PTBD in patients with obstructive jaundice. This
42	study enrolled patients who had undergone percutaneous biliary drainage for acute
43	cholangitis and obstructive jaundice at two institutions between January 2017 and March
44	2024. Fifty-five patients were included in this analysis. However, patients with intrahepatic
45	or hilar bile duct stenosis, post choledocholithiasis, complex cholecystitis, total bilirubin
46	levels $< 2.0$ mg/dL, and uncorrectable bleeding tendency and those who had undergone the
47	procedure and later discontinued without puncture were excluded. The technical success
48	rates, clinical success rates, and complication rates of the procedure were evaluated. The
49	technical success rates were 96.3% (26/27) in the PTGBD group and 82.1% (13/28) in the
50	PTBD group. The clinical success rates were 85.2% (23/27) in the PTGBD group and 67.9%
51	(19/28) in the PTBD group. The complication rates were $11.1\%$ (3/27) in the PTGBD group
52	and 17.9% (5/28) in the PTBD group. Hence, the two groups did not significantly differ in
53	any of the endpoints. The outcomes of PTGBD were comparable to those of PTBD in
54	patients with obstructive jaundice. Hence, PTGBD is a reasonable treatment option for cases
55	of obstructive jaundice in which PTBD is not feasible.

56

## 57 Introduction

58	Bile duct drainage is indicated for all patients with acute cholangitis and obstructive
59	jaundice, except for some mild cases that improve with antimicrobial therapy alone. The
60	Tokyo Guidelines 2018 recommend endoscopic biliary drainage (EBD) as the first-line
61	treatment for bile duct drainage [1]. However, in some cases, EBD cannot be performed due
62	to factors such as the patient's general condition, postoperative reconstructed intestinal tract,
63	and gastrointestinal stenosis. In recent years, endoscopic ultrasound-guided biliary drainage
64	(EUS-BD) has been the salvage procedure of choice for such cases. If EBD and EUS-BD are
65	challenging to perform, percutaneous transhepatic biliary drainage (PTBD) is considered.
66	However, its technical success rate is 63% in patients with nondilated bile ducts and 86% in
67	patients with dilated ducts, which is not sufficient [2].
68	Alternatively, percutaneous transhepatic gallbladder drainage (PTGBD) is a drainage
69	technique for acute cholecystitis. It has a high success rate and can be useful for bile duct
70	drainage if the bile duct obstruction is downstream of the cystic duct. EUS-guided
71	gallbladder drainage has been reported to be useful for EUS-guided hepaticogastrostomy
72	failure in obstructive jaundice [3]. PTGBD can serve as an alternative treatment strategy to
73	PTBD. A case series and a small number of retrospective cohort studies have evaluated the
74	use of PTGBD for cholangitis and obstructive jaundice [4-7]. However, to the best of our

75	knowledge, no studies have compared PTGBD and PTBD. The present study aimed to
76	examine the usefulness of PTGBD and PTBD in patients with obstructive jaundice.

77

### 78 Materials and Methods

#### 79 Study design and participants

80 This retrospective study was based on an analysis of data collected from the patients' 81 electronic medical records. Patients who had undergone percutaneous biliary drainage for 82 acute cholangitis and obstructive jaundice at Showa University Fujigaoka Hospital or Hitachi Medical Center between January 1, 2017 and March 31, 2024 were included in this analysis. 83 84 Patients with intrahepatic or hilar bile duct stenosis, hepaticojejunostomy anastomotic 85 stricture, coexisting cholecystitis, total bilirubin (T.bil) level < 2.0 mg/dL, and uncorrectable 86 bleeding tendency and those who had undergone the procedure and later discontinued 87 without puncture were excluded. 88 The original data were accessed for research purposes on August 16, 2024. The study was conducted according to the Declaration of Helsinki guidelines and was approved 89 by the Showa University Research Ethics Review Board (Approval Number: 2024-106-B). 90 91 Due to the retrospective nature of the study, the need for informed consent was waived by the 92 IRB.

#### 94 Outcomes

95	The primary endpoints were technical success rates, clinical success rates, and
96	complication rates. Technical success was defined as catheter placement into the biliary tract.
97	Clinical success was defined as a decrease in T.bil levels to <2.0 mg/dL or a 50% decrease in
98	T.bil levels after 2 weeks. Complications were evaluated based on the Clavien–Dindo
99	classification [8]. The severity of cholangitis was also assessed using the Tokyo Guidelines
100	2018 [1].
101	
102	Procedure details
103	For percutaneous drainage, PTBD was the first choice, but in cases with poor
104	intrahepatic bile duct dilatation or when bile duct puncture was difficult due to respiratory
105	fluctuations, PTGBD was selected at the surgeon's discretion. PTGBD was performed using a
106	one-step technique (Fig 1). PTBD was performed with either one- or two-step techniques
107	based on the surgeon's discretion (Fig 1). If necessary, analgesics (pentazocine 15 mg) were
108	administered intravenously before puncture.
109	One-step method
110	After administering local anesthesia with lidocaine, an 18-G needle (Hanaco
111	Medical, Saitama, Japan) was inserted into the gallbladder or bile duct under
112	ultrasound guidance, and a small amount of bile was aspirated. Next, a 0.035-in guide wire

113	(Radifocus, Terumo, Tokyo, Japan) was placed in the gallbladder or bile duct under
114	fluoroscopy. After a small skin incision was made and dilated with a dilator, a 6–8-Fr pigtail
115	catheter (UreSil, L.C.C., Illinois, the USA) was inserted.
116	Two-step method
117	After administering local anesthesia with lidocaine, a 20-G needle was inserted
118	under ultrasound guidance. A small amount of bile was aspirated. Then, cholangiography was
119	conducted (Urografine 60%, Byer AG, Nordrhein-Westfalen, Germany). Next, a 0.018-in
120	guide wire was placed in the bile duct under fluoroscopic guidance. A small skin incision was
121	made, an introducer set was inserted, and all but the sheath was removed. Then, a 0.035-in
122	guide wire was inserted, the sheath was removed, and the bile duct was dilated with a dilator.
123	Finally, a 7-Fr pigtail catheter (CLINY PTCD Kit, Create Medic Co., Yokohama, Japan) was
124	implanted.
125	
126	Fig 1. Percutaneous transhepatic gallbladder drainage (PTGBD) and percutaneous
127	transhepatic biliary drainage (PTBD) procedure.
128	(A) 18-G needle was inserted into the gallbladder. Next, a 0.035-in guide wire was placed in
129	the gallbladder. (B) 8-Fr pigtail catheter was inserted. (C) Cholangiography was performed.
130	(D) 18-G needle was inserted into the gallbladder and cholangiography was performed. (E) A
131	0.035-in guide wire was placed in the bile duct. (F) 8-Fr pigtail catheter was inserted.

#### 132

#### 133 Statistical analysis

134	The outcomes of the PTGBD and PTBD groups were compared using the Mann-
135	Whitney U test for continuous variables and chi-square test or Fisher's exact test for nominal
136	variables. A p value of <0.05 was considered statistically significant. R version 4.0.3 (R
137	Foundation for Statistical Computing, Vienna, Austria) was used for data analysis.
138	
139	Results

140

141 Table 1. Comparison of characteristics between percutaneous transhepatic gallbladder

142 drainage and percutaneous transhepatic biliary drainage.

Characteristics	PTGBD (n=27)	PTBD (n=28)	<i>P</i> -value
age (years), median (range)	76 (53-93)	73 (59-95)	0.34
sex (male), n (%)	20 (74.1)	18 (64.3)	0.684
Charlson Comobidity Index, median (range)	7 (3-12)	9 (4-11)	0.0599
use of antithrombotic medication, n (%)	5 (18.5)	4 (14.2)	1
baseline T.bil levels (mg/dl), median (range)	4.30 (2.3-22.7)	9.33 (2.0-26.2)	< 0.01
severe cholangitis, n (%)	14 (51.9)	5 (17.9)	0.0111
etiology of obstruction			
benign, n (%)	18 (66.7)	5 (17.8)	<b>~</b> 0.01
malignant, n (%)	9 (33.3)	23 (82.1)	<0.01
bile duct stone	17	5	
chronic pancreatitis	1	0	
pancreatic cancer	4	12	
bile duct cancer	1	6	

medRxiv preprint doi: https://doi.org/10.1101/2024.09.03.24313028; this version posted September 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . ampullary cancer 1 1 3 gastric cancer 3 0 1 malignant lymphoma reason for ERCP failed or not done, n (%) < 0.01 surgically altered anatomy 13 (48.1) 10 (35.7) duodenal invasion 3 (11.1) 5 (17.9) failed cannulation 4 (14.8) 13 (46.4) 0 respiratory failure or septic shock 7 (25.9) 143 PTGBD: percutaneous transhepatic gallbladder drainage. PTBD: percutaneous transhepatic 144 biliary drainage. ERCP: endoscopic retrograde cholangiopancreatography. 145 **Clinical characteristics of the patients** 146 147 Percutaneous drainage was performed on 79 patients with cholangitis and 148 obstructive jaundice between January 1, 2017, and March 31, 2024. Among them, two 149 presented with hilar bile duct stenosis, seven with hepaticojejunostomy anastomotic stricture, seven with coexisting cholecystitis, and eight with T.bil levels < 2.0 mg/dL were excluded. 150 151 Hence, 55 patients were finally included in this study. 152 Of 55 patients, 27 and 28 underwent PTGBD and PTBD, respectively. One patient 153 in the PTGBD group and five in the PTBD group experienced technical failure. Technical 154 success was 26 in the PTGBD group and 23 in the PTBD group (21 one-step and 2 two-step procedures) (Fig 2). 155 156 In terms of technical failures, in one patient, PTGBD was unsuccessful because the

dilator could not be inserted due to the lack of gallbladder distension. Surgical treatment was

158	then performed. In five patients in whom PTBD failed, three and two underwent PTGBD and
159	EUS-BD, respectively (Fig 2). Table 1 shows the characteristics of the patients. The PTGBD
160	and PTBD groups did not significantly differ in terms of age, sex, and use of antithrombotic
161	medication. The median Charlson Comorbidity Index (CCI) values were 7 (3–12) in the
162	PTGBD group and 9 (4–11) in the PTBD group. The PTBD group (9.33 [2.0–26.2] mg/dL)
163	had significantly higher baseline T.bil levels than the PTGBD group (4.30 [2.3–22.7] mg/dL).
164	Severe cholangitis was significantly more common in the PTGBD group than in the PTBD
165	group (14 [51.9%] vs 5 [17.9%]). In terms of obstruction etiology, 18 (66.7%) and 9 (33.3%)
166	patients in the PTGBD group presented with benign and malignant diseases, respectively.
167	Moreover, 5 (17.8%) and 23 (82.1%) patients in the PTBD group presented with benign and
168	malignant diseases, respectively. Hence, benign disease was more common in the PTGBD
169	group than in the PTBD group. The most common reasons for failure or absence of
170	endoscopic retrograde cholangiopancreatography (ERCP) were postoperative surgically
171	altered anatomy in the PTGBD group ( $n = 13$ [48.1%]) and failed cannulation in the PTBD
172	group (n = 13 [46.4%]) (Table 1).
173	
174	Fig 2. Participant flow chart.

175 PTGBD: percutaneous transhepatic gallbladder drainage. PTBD: percutaneous transhepatic176 biliary drainage.

#### 177

#### 178 Outcomes

179

#### 180 Table 1. Comparison of outcomes between Percutaneous transhepatic gallbladder drainage

#### 181 and percutaneous transhepatic biliary drainage.

	PTGBD (n=27)		
	technical success rates, % (n)	96.3 (26)	
	clinical success rates, % (n)	85.2 (23)	
	complication rates, % (detail)	11.1 (catheter miglation: n=2, shock grade II : n=1)	17.9 (cathe
182			
183	PTGBD: percutaneous transhepatic	gallbladder drainage. PTBD: percutaneous transhepatic	
184	biliary drainage.		
185			
186	The technical success rates	were 96.3% (26/27) in the PTGBD group and 82.1%	
187	(23/28) in the PTBD group. The clin	nical success rates were 85.2% (23/27) in the PTGBD	
188	group and 67.9% (19/28) in the PTBD group. Hence, the two groups did not significantly		
189	differ in terms of technical success	and clinical success rates. Although not included in the	
190	PTBD group, one patient who did n	ot achieve a clinical success to PTGBD achieved a	
191	clinical success to PTBD. The comp	plication rates were 11.1% (3/27) in the PTGBD group	
192	and 17.9% (5/28) in the PTBD grou	p. Thus, there were no significant differences in terms of	
193	the complication rates between the	two groups (Table 2).	

194

#### Discussion 195

196	Cholecystocentesis, which was first reported by Burckhardt and Muller in 1921, has
197	a long history [9]. Subsequently, Huard and Du-Xuan-Hop et al. successfully performed
198	intrahepatic bile duct puncture in 1937 [10]. The introduction of echo-guided puncture and
199	improvements in treatment tools led to therapeutic application of percutaneous biliary
200	puncture. PTBD was first reported by Glenn et al. in 1962 [11]. PTGBD was first reported by
201	Elyaderani and Gabriele in 1979 [12] and performed by Radder in 1982 in patients with acute
202	cholecystitis [13]. To date, in the Tokyo Guidelines, PTGBD is recommended as the standard
203	drainage method for patients with cholecystitis who are at high risk for surgery, and PTBD is
204	an alternative treatment to EBD in patients with cholangitis [1].
205	In recent years, EUS-BD has been gaining popularity as a biliary drainage technique
206	since the study of Giovannini [14]. Moreover, EUS-GBD has been reported to be useful in
207	treating obstructive jaundice in cases of EUS-guided hepaticogastrostomy failure if the bile
208	duct obstruction was downstream of the confluence of the cystic duct. Furthermore, PTGBD
209	may be useful in obstructive jaundice. A case series and a few retrospective cohort studies
210	have long documented the efficacy of PTGBD for obstructive jaundice [4-7].
211	Li et al. and Park et al. reported that PTGBD resulted in jaundice control in 91% (29
212	/ 32) and 100% (20 / 20) of patients with obstructive jaundice. Only 3% (one patient with

213	biliary peritonitis) and 5% (one patient with catheter migration) of patients presented with
214	complications, respectively. And technical success was 100% in both studies. Both studies
215	have revealed that PTGBD is useful in treating obstructive jaundice [4, 5].
216	No reports have compared PTGBD and PTBD. This is the first report comparing the
217	efficacy of PTGBD and PTBD in obstructive jaundice. The technical success, clinical
218	success, and complication rates of PTGBD and PTBD were comparable in this study.
219	PTGBD for obstructive jaundice should be considered as an alternative treatment to PTBD.
220	However, in one case, PTBD improved jaundice in a patient who showed no clinical response
221	to PTGBD. Treatment via the percutaneous drainage route (rendezvous procedure,
222	percutaneous bile duct stenting, and stone removal) is also less difficult with PTBD than with
223	PTGBD. In patients considering treatment via the percutaneous drainage route, PTBD can
224	be a better option because of the ease of subsequent procedures.
225	Although there were no significant differences in terms of outcomes between the
226	two groups, the clinical characteristics of the two groups differed. In terms of disease
227	etiology, benign diseases such as common bile duct stones were more common in the
228	PTGBD group than in the PTBD group. Meanwhile, malignant diseases were more common
229	in the PTBD group than in the PTGBD group. Severe cholangitis was significantly more
230	common in the PTGBD group than in the PTBD group. Severe cholangitis caused by bile
231	duct stones requires a short treatment time due to unstable vital signs. In several cases, it is

232	difficult to obtain patient cooperation and respiratory arrest at the time of puncture.
233	Therefore, PTGBD, which is less difficult to perform, was selected. By contrast, obstructive
234	jaundice caused by malignant diseases is generally more severe than that caused by benign
235	disease. However, it is less likely to be complicated by severe cholangitis. The high degree of
236	bile duct dilatation and the ease of patient cooperation might have been the reasons for
237	selecting PTBD. The PTBD group can have a higher CCI than the PTGBD group because of
238	the higher number of patients with malignant diseases. There were no statistically significant
239	differences. However, it should not be underestimated that the PTGBD group was more
240	likely to have a higher technical success rate and a lower incidence rate of accidents.
241	The greatest advantage of PTGBD is its ease of use and high technical success rate.
242	PTGBD and PTBD should be used interchangeably in different cases. However, in cases
243	where PTBD is challenging to perform, PTGBD should be considered as an alternative
244	treatment.
245	The present study had several limitations. First, it was a retrospective study
246	conducted at two centers, and the number of cases was small. The two groups differed in
247	terms of clinical characteristics, with the PTGBD group having milder jaundice. The type of
248	procedure might have been influenced by the operator's subjective bias. Future studies
249	comparing PTBD and PTGBD under identical conditions should be performed.
250	

## 251 Conclusions

252	The outcomes of PTGBD are comparable with those of PTBD in patients with
253	obstructive jaundice. Thus, PTGBD is a reasonable treatment option in cases of obstructive
254	jaundice in which the intrahepatic bile duct dilatation is poor or PTBD is challenging to
255	perform due to the patient's general condition.
256	
257	Acknowledgments
258	None.
259	
260	References
261	[1] Yokoe M, Hata J, Takada T, Strasberg SM, Asbun HJ, Wakabayashi G, et al. Tokyo
262	Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos).
263	J Hepatobiliary Pancreat Sci. 2018;25(1): 41-54.
264	[2] Saad WE, Wallace MJ, Wojak JC, Kundu S, Cardella JF. Quality improvement guidelines
265	for percutaneous transhepatic cholangiography, biliary drainage, and percutaneous
266	cholecystostomy. J Vasc Interv Radiol. 2010;21(6): 789-95.
267	[3] Imai H, Kitano M, Omoto S, Kadosaka K, Kamata K, Miyata T, et al. EUS-guided
268	gallbladder drainage for rescue treatment of malignant distal biliary obstruction after
269	unsuccessful ERCP. Gastrointest Endosc. 2016;84: 147-151.

- 270 [4] Park JM, Kang CD, Lee M, Park SC, Lee SJ, Jeon YH, et al. Percutaneous
- 271 cholecystostomy for biliary decompression in patients with cholangitis and pancreatitis. J Int
- 272 Med Res. 2018;46(10): 4120-4128.
- 273 [5] Li YL, Wong KH, Chiu KW, Cheng AK, Cheung RK, Yam MK, et al. Percutaneous
- cholecystostomy for high-risk patients with acute cholangitis. Medicine (Baltimore).
- **275** 2018;97(19):e0735.
- 276 [6] Ren Z, Xu Y, Zhu S. Percutaneous transhepatic cholecystostomy for choledocholithiasis
- with acute cholangitis in high-risk patients. Hepatogastroenterology. 2012;59: 329-331.
- 278 [7] Shitrit AB-G, Braverman D. Interval percutaneous cholecystostomy is effective for
- 279 decompression of the common bile duct in high-risk elderly patients prior to endoscopic
- retrograde cholangiopancreatography. Gerontology. 2008;54: 144-147.
- [8] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new
- proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg.
- **283** 2004;240(2): 205-13.
- [9] Burckhardt H, Muller W. Study on the puncture of the gallbladder and their X-ray
- 285 imaging. Dtsch Z Chir. 1921;162: 168-197.
- [10] Huard P, Du-Xuan-Hop. Transhepatic bile duct puncture. Bull Soc Med Chir
- **287** Indochine. 1937;15: 1090-1110.

- 288 [11] Glenn F, Evans JA, Mujahed Z, Thorbjarrnarson B. Percutaneous transhepatic
- 289 cholangiography. Ann Surg. 1962;156: 451-460.
- [12] Elyaderani M, Gabriele OF. Percutaneous cholecystostomy and cholangiography in
- patients with obstructive jaundice. Radiology. 1979;130: 601-602.
- [13] Radder RW. Percutaneous cholecystostomy. AJR Am J Roentgenol. 1982;139: 1240-
- **293** 1241.
- 294 [14] Giovannini M, Moutardier V, Pesenti C, Bories E, Lelong B, Delpero JR. Endoscopic
- 295 ultrasound-guided bilioduodenal anastomosis: a new technique for biliary drainage.
- **296** Endoscopy. 2001;33: 898-900.
- 297



# Figure1



Figure2